TREK 2018 - the Fifth Annual International Transradial Endovascular Course - was held in Moscow on January 26-27, 2018. The Transradial Endovascular Course is one of the leading symposiums in Russia in the field of interventional cardioangiology. Angioline supported the event as a general sponsor, and its products were featured in the exhibition of manufacturers held as part of the course. On the second day of the course, Angioline held a lunch-symposium for its participants on the clinical program of Calypso, during which the first public presentation of the results of the PATRIOT study (Calipso vs Xience) was held. The moderator of the discussion was Avtandil Babunashvili, the Head of the Cardiovascular Surgery Department of the Center of Endosurgery and Lithotripsy, Multi-Discipline Clinic (CELT, MC), Dr. habil. med., professor at the Academic Department of Hospital Surgery of the Peoples Friendship University of Russia. The results of the PATRIOT study were presented to the audience by its chief coordinator Yevgeny Kretov, doctor of x-ray endovascular diagnostics and treatment at the E.N. Meshalkin's National Medical Research Center of the Ministry of Health of Russia (Novosibirsk). In turn, Dr. Alexei Prokhorikhin from Novosibirsk shared his vision of the future prospects of the Calypso stent in cardiovascular surgery, and Oleg Volkov, medical director of Angioline, spoke about the design and interpretation of clinical researches in interventional cardiology. TREK 2018 was organized by the Russian Scientific Society of Interventional Surgeons, the Russian Scientific Medical Society of Physicians, and the Center of Endosurgery and Lithotripsy, Multi-Discipline Clinic. Every year, well-known Russian and international experts in the field of interventional medicine take part in the course.

Подписавшись на рассылку новостей мы гарантируем, что будем отправлять не более одного - два письма в месяц. Основными темами рассылок будут достижения компании в области разработки оборудования и аксессуаров для ангиопластики.